Detalhe da pesquisa
1.
IGFBP7 is not required for B-RAF-induced melanocyte senescence.
Cell
; 141(4): 717-27, 2010 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-20478260
2.
Whole-genome landscapes of major melanoma subtypes.
Nature
; 545(7653): 175-180, 2017 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28467829
3.
Musculoskeletal immune-related adverse events with the use of checkpoint inhibitors in malignancy.
Intern Med J
; 52(5): 818-827, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33135853
4.
First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies.
Invest New Drugs
; 39(4): 1047-1056, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33594602
5.
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations.
J Med Genet
; 57(5): 316-321, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30291219
6.
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.
Lancet Oncol
; 21(3): 358-372, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32007138
7.
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
N Engl J Med
; 377(19): 1813-1823, 2017 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28891408
8.
bcGST-an interactive bias-correction method to identify over-represented gene-sets in boutique arrays.
Bioinformatics
; 35(8): 1350-1357, 2019 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30215668
9.
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(5): 701-710, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30928620
10.
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.
Lancet Oncol
; 20(7): 961-971, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171444
11.
Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility.
Int J Cancer
; 144(5): 1049-1060, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30178487
12.
Liquid biomarkers in melanoma: detection and discovery.
Mol Cancer
; 17(1): 8, 2018 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29343260
13.
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Lancet Oncol
; 18(9): 1202-1210, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28729151
14.
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.
Br J Cancer
; 116(12): 1558-1563, 2017 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28524161
15.
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma.
Nature
; 480(7375): 99-103, 2011 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-22080950
16.
Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in Australia.
Intern Med J
; 47(8): 888-893, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28485058
17.
Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.
Br J Cancer
; 115(11): 1280-1284, 2016 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27711085
18.
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
N Engl J Med
; 369(2): 134-44, 2013 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-23724846
19.
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
J Am Acad Dermatol
; 74(3): 455-61.e1, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26793994
20.
Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment.
J Immunol
; 192(5): 2505-13, 2014 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24489105